<p>To ask Her Majesty's Government, further to the Written Answers by Lord O’Shaughnessy on 15 November (HL11187 and HL11188), what data are recorded by the Medicines and Healthcare products Regulatory Agency’s pharmacovigilance work and the Yellow Card Scheme regarding drugs and dosages administered to women during IVF treatment and early pregnancy; to what extent this includes off-label drugs in order to monitor their long-term effects on women undergoing IVF treatment; how this compares to the collection of such data in other countries; and why the Human Fertilisation and Embryology Authority has no plans to establish a central database to monitor the long-term health implications of the medicines administered to women during IVF.</p>